Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Inclusion criteria: * CTCL: Biopsy-confirmed MF or SS stages IB-IVA2. * Patients who have SS with bone marrow involvement are also eligible. * Patients with transformed CTCL are eligible. * ATL: Patient with cytologically or histopathologically confirmed lymphoma. * Lymphoma should be identified as tumors derived peripheral T-cells by cell surface marker. * ATL: Patients with positivity for anti-HTLV-1 antibody * Patients must have received at least two systemic therapy regimens. * Patients must have had disease progression on or following their most recent treatment regimen. * Age ≥ 20 years * ECOG Performance Status of ≤ 2 * Written informed consent obtained prior to any study specific screening procedures Exclusion criteria: * Patients with a history of primary CNS tumors * Any history or presence of brain metastases * Patients with any peripheral neuropathy ≥ CTCAE grade 2 * Patients with unresolved diarrhea \> CTCAE grade 1 * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589 * Patients with concurrent severe and/or uncontrolled liver or renal disease * Patients using sodium valproate ≤5 days prior to starting study drug * Patients with an active bleeding diathesis or on any treatment with therapeutic doses of sodium warfarin or other antivitamin K drugs * Patients who have received any investigational drug or chemotherapy or undergone major surgery ≤ 3 weeks prior to starting study drug or who have not recovered from side effects of such therapy * Patients who have received biologic therapy, target therapy (e.g. denileukin diftitix ), vaccine, systemic steroids or immunotherapy ≤ 2 weeks prior to starting study treatment or who have not recovered from side effects of such therapy * Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy